Six years af­ter a spec­tac­u­lar de­but, Warp Dri­ve Bio is pow­er­ing down and hand­ing its 'un­drug­gable' am­bi­tions over to Rev­o­lu­tion

Close to six years af­ter Third Rock launched Warp Dri­ve Bio with a big-mon­ey col­lab­o­ra­tion from Sanofi and am­bi­tious plans to drug the un­drug­gable with new tech out of Har­vard, the biotech has reached the end of the line as an in­de­pen­dent op­er­a­tion. 

To­day Warp Dri­ve is dis­patch­ing its pipeline to an­oth­er Third Rock start­up com­pa­ny, Rev­o­lu­tion Med­i­cines, with the CEOs of both com­pa­nies in­sist­ing that this is a win-win for all in­volved, though Warp Dri­ve nev­er ac­tu­al­ly made the leap in­to the clin­ic.

Lau­rence Reid

Pressed on the point, Warp Dri­ve CEO Lau­rence Reid con­cedes that every de­ci­sion like this has its “up­sides and down­sides,” but he in­sists that the de­ci­sion by the board rep­re­sents the best path for­ward for in­vestors as well as the med­i­cines they have been toil­ing on since 2012.

Warp Dri­ve was a biotech child of its time. The com­pa­ny boast­ed of a ”ge­nom­ic search en­gine” that “en­ables hid­den nat­ur­al prod­ucts to be re­vealed on the ba­sis of their dis­tinc­tive ge­nom­ic sig­na­ture.” And with the likes of Greg Ver­dine — who left to do 2 new star­tups — and George Church out of Har­vard be­hind it, there were plen­ty of be­liev­ers.

What­ev­er the two CEOs say to­day about all the pos­i­tives be­hind the deal, any biotech com­pa­ny that goes six years with­out get­ting in­to the clin­ic — or an­nounc­ing plans to — is like­ly to get a thor­ough re­view from in­vestors. Reid, though, says that Third Rock and the oth­er in­vestors were will­ing to go back in­to a Se­ries B, the orig­i­nal plan for fi­nanc­ing the next step, be­fore the board set this new path out.

The fate of the 43 staffers?

Mark Gold­smith

That’s still to be de­cid­ed, says CEO Mark Gold­smith of Rev­o­lu­tion, which on­ly re­cent­ly un­der­went a tran­si­tion to on­col­o­gy af­ter aban­don­ing its ear­ly work on an an­ti-fun­gal. Ob­vi­ous­ly, he added, not every­one will make the jump from the East to the West Coast where Rev­o­lu­tion is based, and that in it­self will mean some re­duc­tion in staff.

The big Sanofi col­lab­o­ra­tions that were her­ald­ed in an­tibi­otics and on­col­o­gy? Those end­ed in 2017 and 2016, says Reid. And the lights went out on those part­ner­ships with­out any of the rah-rah that at­tend­ed their ar­rival.

Sanofi cur­rent­ly has 40% of the eq­ui­ty in Warp Dri­ve, with no rights to any of its prod­ucts.

How much is that worth af­ter the deal goes through, with Rev­o­lu­tion hand­ing out stock to in­vestors?

They aren’t say­ing.

The two oth­er col­lab­o­ra­tions that were formed with Glax­o­SmithK­line and Roche, which front­ed $87 mil­lion for the up­front and pre­clin­i­cal mile­stones? Con­tin­u­ing un­der re­view, to be de­cid­ed on lat­er, af­ter Rev­o­lu­tion’s ex­ec team “de­ter­mines its busi­ness strat­e­gy for the genome min­ing plat­form.”

Gold­smith al­so hit a va­ri­ety of up­beat notes about the deal, say­ing this would bring to­geth­er two high­ly com­ple­men­tary pipelines and al­low a more rapid de­vel­op­ment of the Warp Dri­ve as­sets.

Asked when the most ad­vanced Warp Dri­ve pro­gram could ex­pect to en­ter the clin­ic, Gold­smith replied that they aren’t pro­vid­ing time­lines.

 

Am­gen lays off about 300 work­ers, cit­ing 'in­dus­try head­wind­s'

Amgen has laid off about 300 employees, a company spokesperson confirmed to Endpoints News via email Sunday night.

Employees posted to LinkedIn in recent days about layoffs hitting Amgen last week. The Thousand Oaks, CA-based biopharma, which employs about 24,000 people, said the reduction “mainly” impacted US-based workers on its commercial team.

Drug developers of all sizes, including small upstarts and pharma giants, have let employees go in recent months as the biopharma market drags through a quarters-long winter doldrum.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bob Bradway, Amgen CEO (Stephen Lam/Reuters)

Am­gen launch­es the first US Hu­mi­ra biosim­i­lar at two dif­fer­ent list prices

The bizarre dynamics of the US prescription drug market were on full display once again this morning as Amgen announced that it would launch the first US biosimilar for Humira, the best-selling drug of all time, at two completely different list prices.

One price for Amgen’s Amjevita (adalimumab-atto) will be 55% below the current Humira list price, which is about $84,000 per year, and another at a list price 5% below the current Humira list price, but presumably (pharma companies don’t disclose rebates) with high rebates to attract PBMs and payers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Credit: Shutterstock

New York City in­vests $20M in­to biotech 'in­no­va­tion space' at the Brook­lyn Navy Yard

New York City is investing $20 million in biotech this year in the form of a 50,000-square-foot “innovation space” at the Brooklyn Navy Yard, complete with offices, research laboratories and events and programming space to grow biotech startups and companies.

Mayor Eric Adams said during his State of The City Address last Thursday that there will be an “emphasis” on making more opportunities for women and people of color to further diversify the industry. The City first reported the news.

Dirk Thye, Quince Therapeutics CEO

Af­ter piv­ot­ing from Alzheimer's to bone con­di­tions, biotech piv­ots again — and halves its head­count

When troubled public biotech Cortexyme bought a private startup named Novosteo and handed the keys to its executive team, the company — which changed its name to Quince Therapeutics — said it would shift its focus from an unorthodox Alzheimer’s approach to Novosteo’s bone-targeting drug platform.

Less than a year later, Quince is pivoting again.

The biotech has decided to out-license its bone-targeting drug platform and its lead drug, NOV004, and instead look for clinical-stage programs to in-license or acquire, according to a press release.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Boehringer In­gel­heim touts pre­ven­tion re­sults in rarest form of pso­ri­a­sis

Boehringer Ingelheim uncorked some positive results suggesting that Spevigo can help prevent flare-ups in patients with a severe form of psoriasis, months after the drug was approved to treat existing flares.

Spevigo, an IL-36R antibody also known as spesolimab, met its primary and a key secondary endpoint in the Phase IIb EFFISAYIL 2 trial in patients with generalized pustular psoriasis (GPP), Boehringer announced on Monday. While the company is keeping the hard numbers under wraps until later this year, it said in a news release that it anticipates sharing the results with regulators.

As­traZeneca, No­vo Nordisk and Sanofi score 340B-re­lat­ed ap­peals court win over HHS

AstraZeneca, Novo Nordisk, and Sanofi won an appeals court win on Monday, as the US Court of Appeals for the Third Circuit found that the companies cannot be forced to provide 340B-discounted drugs purchased by hospitals from an unlimited number of community and specialty pharmacies.

“Legal duties do not spring from silence,” the decision says as the court makes clear that the federal government’s interpretation of the “supposed requirement” that the 340B program compels drugmakers to supply their discounted drugs to an unlimited number of contract pharmacies is not correct, noting:

Ap­peals court toss­es J&J's con­tro­ver­sial 'Texas two-step' bank­rupt­cy case

A US appeals court has ruled against Johnson & Johnson’s use of bankruptcy to deal with mounting talc lawsuits, deciding that doing so would “create a legal blind spot.”

The Third Circuit Court of Appeals reversed a previous bankruptcy court decision on Monday, calling for the dismissal of a Chapter 11 filing by J&J’s subsidiary LTL Management.

Faced with more than 38,000 lawsuits alleging its talc-based products caused cancer, J&J spun its talc liabilities into a separate company called LTL Management back in October 2021 and filed for bankruptcy, a controversial move colloquially referred to as a “Texas two-step” bankruptcy. Claimants argued that the strategy is a misuse of the US bankruptcy code — and on Monday, a panel of judges agreed.

Chad Mirkin, Flashpoint co-founder

‘The field is at a flash­point’: New Chad Mirkin-found­ed biotech hopes to make more ef­fec­tive can­cer vac­cines

Following the success of the mRNA Covid vaccines, cancer vaccines are seeing renewed interest after years of middling results. But a group of researchers suggests that more attention needs to be paid not to what goes into those vaccines, but how the parts are put together.

In a recent paper published in Nature Biomedical Engineering, researchers led by Northwestern University’s Chad Mirkin describe how the placement of different antigens in a cancer vaccine impacts its efficacy. The paper builds on past work done by Mirkin’s lab that suggests the structure, or how the parts of a vaccine are arranged, impact a vaccine’s efficacy, not just its components.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

#JPM23: Reg­u­la­to­ry un­cer­tain­ty? What about M&A? Da­ta rule? Alessan­dro Masel­li and John Car­roll take out their crys­tal balls

Endpoints editor and founder John Carroll sat down the Catalent CEO Alessandro Maselli to talk about what’s ahead in 2023. Right or wrong, this covers all the big issues faced by biopharma. This transcript has been edited for brevity and clarity.

John Carroll:

I think 2022 had to be one of the worst years ever for crystal balls. You went into 2022 thinking all sorts of nice things about what was ahead, not thinking about a European land war, maybe not thinking that the Federal Reserve was going to be jacking up interest rates as fast as they could to get ahead of inflation. Just a tremendous number of macroeconomic issues that were out there. The sudden and complete collapse of support on the markets in Nasdaq for biotech. A lot of darlings in the industry that had been out there for a while suddenly found themselves moving from a really hot market to a really cold market all of a sudden and had to make a lot of different changes in terms of strategizing.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.